Abstract 40P
Background
Immune checkpoint inhibitors have become standard of care for many cancer subtypes. Next generation immuno-oncology (IO) agents are in clinical testing, with thousands of combinations in preclinical evaluation. The success of current and future immunotherapies relies on tools, data and technology to rationalize their use and manage toxicity. However, few biomarkers can distinguish responders from non-responders, predict toxicity, or guide treatment choices.
Methods
MANIFEST (https://www.manifest-io.org.uk/), a UKRI/MRC funded platform, leverages scalable methodologies to provide deep profiling of patients receiving immunotherapy; delivering multimodal data integration and modelling. The platform comprises NHS trusts (hospitals), research institutes and universities, and industry partners. The aims of MANIFEST is to harmonise sampling, assays and analyses of IO biomarkers and couple them with large-scale studies in patients with cancer. The platform’s utility will be demonstrated with exemplar projects encompassing multiple tumour types (melanoma, renal cell carcinoma, bladder cancer and triple-negative breast cancer), where predicting treatment outcomes and toxicities remains an unmet need.
Results
We have access to longitudinal samples of >3,000 patients across 10 reported studies. Through partner NHS sites, we aim to prospectively collect and profile samples (blood, stool and tumour) from ∼3,000 patients over 3 years. A tiered approach will implement workflows for high-volume biomarker discovery (Tier 1). In-depth profiling (Tiers 2&3) will further characterize tumours using peripheral immune profiling including high-dimensional flow cytometry, liquid biopsy (cfDNA, immune methylation profiling), spatial tissue image-profiling and molecular profiling (WES, bulk&long-read RNAseq, TCR&BCRseq). For selected patients, we will apply Representative Sequencing (RepSeq), to overcome sampling bias in solid tumours and conduct drug-sensitivity screening through patient-derived tumour fragments.
Conclusions
Machine learning will be applied to derive uni- and multi- modal biomarkers of response and toxicity, and the master databases will be available for ongoing academic and industry research.
Legal entity responsible for the study
The Francis Crick Institute & The MANIFEST Consortium.
Funding
UKRI, Medical Research Council and Office of Life Sciences.
Disclosure
T. Lawley: Financial Interests, Institutional, Leadership Role: Microbiotica. All other authors have declared no conflicts of interest.
Resources from the same session
216P - Spatial transcriptomics reveals tumor-microenvironment heterogeneity of breast cancer
Presenter: Hyun Lee
Session: Poster Display session
Resources:
Abstract
217P - Tumor-derived CCL15 regulates RNA m6A methylation in cancer-associated fibroblasts to promote hepatocellular carcinoma growth
Presenter: Yueguo Li
Session: Poster Display session
Resources:
Abstract
218P - A novel tumor adenosine signature to guide indication selection for adenosine pathway inhibitors
Presenter: Sophie Dekoninck
Session: Poster Display session
Resources:
Abstract
219P - Radiotherapy, in conjunction with a PI3Kd/? inhibitor, enhances effector CD8+ T cell-mediated anti-tumor immune responses and the memory function of T cells within the tumor microenvironment by stimulating innate immunity
Presenter: Ye hyun Kim
Session: Poster Display session
Resources:
Abstract
220P - Correlation research between oral flora diversity and radiation-induced stomatitis after postoperative radiotherapy for oral squamous cell carcinoma
Presenter: Qin Zheng
Session: Poster Display session
Resources:
Abstract
221P - Chemoradiotherapy induced adaptive anti-tumor T cell immunity in patients with non-small cell lung cancer
Presenter: Yaoyao Xie
Session: Poster Display session
Resources:
Abstract
222P - Features of epithelial-to-mesenchymal transition (EMT) and humoral immune response in ulcerated acral melanoma: A transcriptomic and spatial proteomic analysis.
Presenter: Estefania Vazquez
Session: Poster Display session
Resources:
Abstract
223P - Frequency of the number of myeloid-derived suppressor cells in patients with lung cancer according to T stage
Presenter: Jelena Vukovic
Session: Poster Display session
Resources:
Abstract
224P - Immunological Dynamics in Triple-Negative Breast Cancer: Peripheral Immune Responses to Neoadjuvant Therapy
Presenter: Rita Santos
Session: Poster Display session
Resources:
Abstract
225P - Assessment of immune cell populations in the peripheral blood of metastatic prostate cancer
Presenter: Vanessa Patel
Session: Poster Display session
Resources:
Abstract